News ImmuneRegen NewsImmuneRegen BioSciences, Inc. Plans to Establish a Response TeamSCOTTSDALE, Ariz., April 19 /PRNewswire/ -- It has been requested by the U.S. FDA (Food & Drug Administration) and the newly formed Department of Counter Terrorism (DCT) that ImmuneRegen BioSciences, Inc. considers establishing a response team to effectively react in the event of an act of bio-terrorism and/or chemical disaster. This request was made in the minutes delivered to the senior management team during their FDA meeting in Washington for Acute Radiation Sickness (ARS) on March 12th 2004."For our company, this request serves as confirmation that the governing body of drug treatments sees promise that a potential treatment or prophylaxis for this indication can be available," says Michael Wilhelm. "This is a great step for the company."The company will soon be initiating a study to determine the most effective form of administration of its proprietary compound "Homspera" for this indication. For ARS, the company currently administers "Homspera" via aerosol, and we are determining if there is greater efficacy and ease of use through a direct muscle injection. The team will be lead by the company's acting CSO & Founder, Dr. Mark Witten, and ImmuneRegen is determining the other members best fit for the team. We expect to have the team established and all other necessary implementation in place shortly after we complete the upcoming administration/delivery study. About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|